As of May 24
| +1.20 / +0.87%|
The 19 analysts offering 12-month price forecasts for Intercept Pharmaceuticals Inc have a median target of 212.00, with a high estimate of 515.00 and a low estimate of 80.00. The median estimate represents a +51.65% increase from the last price of 139.80.
The current consensus among 20 polled investment analysts is to Buy stock in Intercept Pharmaceuticals Inc. This rating has held steady since May, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.